Collagen Peptide Mixture for Diabetes via Enzymatic Segmentation

The patent replaces synthetic pharmaceutical products with peptides obtained from food or drink materials through enzymatic degradation. These natural peptides are designed to be temporary, biodegradable molecules that perform the therapeutic function without accumulating in the body, thereby reducing long-term side effects while maintaining acute therapeutic efficacy.

The patent changes the chemical parameters of the active compounds by using enzymatically degraded peptides from natural food sources instead of synthetic molecules. This parameter change transforms the drug from a synthetic chemical compound to a biologically derived peptide, altering its metabolic pathway and reducing harmful side effects like hypoglycemia while preserving DPPIV inhibitory activity.

The patent applies segmentation by breaking down collagen from food materials into smaller peptide fragments through controlled enzymatic degradation. Instead of using intact long peptides that cannot be absorbed, the collagen is segmented into smaller units that retain DPPIV inhibitory activity while being small enough to cross the intestinal barrier and be absorbed into the bloodstream.

The patent changes the molecular size parameter of the peptides by controlling the degree of enzymatic degradation. The degradation is optimized to produce peptides of a specific size range - small enough for intestinal absorption but large enough to maintain the structural features necessary for DPPIV inhibitory activity and GLP-1 secretion acceleration.